热门资讯> 正文
Neoleukin prices equity offering at $8.40
2019-12-18 11:05
Neoleukin Therapeutics (NASDAQ:NLTX) prices its public offering of 8,925,000 common shares at $8.40 per share, for expected gross proceeds of ~$75M.
Closing date is December 20.
Underwriters' over-allotment is an additional 1,338,750 shares.
Net proceeds will be used to advance development of NL-201, to expand itsde novoprotein design technology, to fund working capital and for general corporate purposes.
Shares are up2%premarket.
Click to subscribe to real-time analytics on NLTX
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
